Treatment of acute respiratory distress syndrome with recombinant surfactant protein C surfactant
Treatment of acute respiratory distress syndrome with recombinant surfactant protein C surfactant
复制标题
DOI：
10.1164/rccm.200207-782oc
复制
发表时间：
2003-06-01
影响因子：
24.7
通讯作者：
Marsh, JJ
中科院分区：
文献类型：
--
作者：
Spragg, RG;Lewis, JF;Marsh, JJ
我们在北美进行了一项I/II期试验，以重组表面活性剂蛋白c为基础的表面活性剂（Venticute）作为急性呼吸窘迫综合征的治疗。患者前瞻性随机接受标准治疗或标准治疗加两剂外源性表面活性剂中的一剂，在24小时内给予4次。表面活性剂耐受性良好。表面活性剂处理没有显著的治疗效果。治疗后48小时的支气管肺泡灌洗反映了外源性表面活性剂成分的存在，没有显示出表面张力降低功能的改善，并且白细胞介素-6浓度显著低于对照组值，与抗炎治疗效果一致。120小时的灌洗液中未检测到外源性表面活性剂的存在。未来的研究可能会合理地采用更大的表面活性剂剂量和更长的给药时间。
We performed a phase I/II trial in North America of a recombinant surfactant protein C-based surfactant (Venticute) as treatment for the acute respiratory distress syndrome. Patients were prospectively randomized to receive either standard therapy or standard therapy plus one of two doses of exogenous surfactant given four times over 24 hours. Surfactant administration was well tolerated. No significant treatment benefit was associated with surfactant treatment. Bronchoalveolar lavage of treated patients at 48 hours reflected the presence of exogenous surfactant components, did not show evidence of improved surface tension lowering function, and had interleukin-6 concentrations that were significantly lower than control group values, consistent with an antiinflammatory treatment effect. The presence of exogenous surfactant was not detected in lavage fluid obtained at 120 hours. Future studies might rationally employ larger surfactant doses and a more prolonged dosing schedule.